Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

27 May 2015

Abstract excerpt

// José Luis Ordóñez 1,4,* , Ana Teresa Amaral 1,4,* , Angel M. Carcaboso 2 , David Herrero-Martín 3 , María del Carmen García-Macías 4 , Vicky Sevillano 4 , Diego Alonso 4 , Guillem Pascual-Pasto 2 , Laura San-Segundo 4 , Monica Vila-Ubach 2 , Telmo Rodrigues 4 , Susana Fraile 4 , Cristina Teodosio 4 , Agustín Mayo-Iscar 5 , Miguel Aracil 6 , Carlos María Galmarini 6 , Oscar M. Tirado 3 , Jaume Mora 2 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26056084
DOI: 10.18632/oncotarget.4303

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedinPMID 26056084Read ↗

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2Semantic proximity Read ↗

The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor ToxicitySemantic proximity Read ↗

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s SarcomaSemantic proximity Read ↗

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndromeSemantic proximity Read ↗

Targeting the DNA Repair Pathway in Ewing SarcomaSemantic proximity Read ↗

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathwaysSemantic proximity Read ↗

Efficacy of ATR inhibitors as single agents in Ewing sarcomaSemantic proximity Read ↗

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasSemantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged SwordSemantic proximity Read ↗

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeuticsSemantic proximity Read ↗

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.